Auris Medical Holding (EARS) Starts Presentation at LD Micro Main Event
Auris Medical Holding AG (NASDAQ: EARS) is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The program is currently in phase 1. In addition, Auris Medical has two phase 3 programs under development: AM-111 for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. Founded in 2003, the company is headquartered in Zug, Switzerland. For more…







